PubHawk
Biomaterials August 2021 PMID 34062420

Design of enzyme-responsive short-chain fatty acid-based self-assembling drug for alleviation of type 2 diabetes mellitus.

Babita Shashni, Yuya Tajika, Yukio Nagasaki

Download social card

Mentions

4
Peak: 2 in Oct 2021
across 2 sources since Jun 2021

Extended reach

1,290
potential audience

Total likes

0

Video views

324

Mentions per month

Jun 2021 – Oct 2021

Where it's discussed

  • YouTube3 videos
  • X / Twitter1 posts

AI synopsis

What people are saying

The discussions highlight enthusiasm about the innovative enzyme-responsive nanoparticles that address limitations of traditional SCFA treatments, with comments like 'game-changing approach' and 'promising therapeutic strategy.' The tone reflects a mix of curiosity and cautious optimism, emphasizing the potential for real-world applications.

AgreementModerate agreement

Most discussions acknowledge the novelty and potential benefits of the proposed drug delivery system, reflecting a general consensus that this approach could improve diabetes treatment.

InterestModerate interest

Users show moderate interest, as many express curiosity about how the enzyme responsiveness enhances SCFA delivery and its clinical relevance.

EngagementHigh engagement

Several discussions delve into technical details, mentioning nanoparticle design, biocompatibility, and delivery mechanisms, indicating substantial engagement.

ImpactModerate impact

There is recognition of the possible significant impact on future diabetes therapies, especially regarding improved efficacy and patient compliance.

Abstract in brief

  • Short-chain fatty acids (SCFAs) like propionic and butyric acids are promising for treating diabetes but have limitations in clinical use, such as poor taste and odor.
  • To address these issues, researchers created enzyme-metabolizable block copolymer nanoparticles that deliver SCFAs more effectively in a mouse model of type 2 diabetes.
  • The results showed that these nanoparticles had better therapeutic effects than low-molecular-weight SCFAs due to improved palatability, longer presence in the gastrointestinal tract, and fewer side effects.
Read the full abstract

Top posts

Most liked on X and Bluesky
Dataemia
@Dataemia · X

(Design of enzyme-responsive short-chain fatty acid-based self-assembling drug for alleviation of type 2 diabetes mellitus) https://t.co/18hc6fdTZh

Jun 2, 2021 · 966 followers View post →

All mentions

Dataemia
@Dataemia · X

(Design of enzyme-responsive short-chain fatty acid-based self-assembling drug for alleviation of type 2 diabetes mellitus) https://t.co/18hc6fdTZh

Jun 2, 2021 · 966 followers View post →